Search

Your search keyword '"Carreno-Tarragona G"' showing total 2 results
Start Over Author "Carreno-Tarragona G" Topic thrombocythemia, essential
2 results on '"Carreno-Tarragona G"'

1. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.

Author

Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, and Vannucchi AM

Subjects
Aged, Aged, 80 and over, Bone Marrow Neoplasms complications, COVID-19 complications, Cohort Studies, Europe epidemiology, Female, Humans, Male, Middle Aged, Myeloproliferative Disorders complications, Pandemics, Retrospective Studies, Risk Factors, SARS-CoV-2 physiology, Thrombocythemia, Essential complications, Bone Marrow Neoplasms epidemiology, COVID-19 epidemiology, Myeloproliferative Disorders epidemiology, Thrombocythemia, Essential epidemiology, Venous Thromboembolism epidemiology, Venous Thromboembolism etiology
Abstract

In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (-23.3%, p < 0.0001) than in PV (-16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs.

Published
2021
Full Text
View/download PDF

2. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

Author

Alvarez-Larran A, Angona A, Andrade-Campos M, Noya M, Gomez-Casares M, Cuevas B, Caballero G, Garcia-Hernandez C, Garcia-Gutierrez V, Palomino A, Ferrer-Marin F, Mata-Vazquez M, Moreto A, Magro E, Murillo I, Alonso-Dominguez J, Guerra J, Guerrero L, Raya J, Perez-Encinas M, Carreno-Tarragona G, Fox L, Pastor-Galan I, Bellosillo B, Hernandez-Boluda J, and MPN Spanish Grp GEMFIN

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Genotype, genotype, Mutation, Missense, essential thrombocythaemia, Gastroenterology, myeloproliferative neoplasms, Hydroxycarbamide, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Humans, Hydroxyurea, In patient, Registries, Child, Aged, haematological response, Aged, 80 and over, therapy, Haematological response, business.industry, Essential thrombocythemia, Hematology, Anagrelide, Janus Kinase 2, Middle Aged, medicine.disease, Amino Acid Substitution, Treatment modality, Median time, Spain, 030220 oncology & carcinogenesis, Quinazolines, Female, calreticulin mutation, business, Calreticulin, 030215 immunology, medicine.drug, Follow-Up Studies, Thrombocythemia, Essential
Abstract

The present study assessed the criteria for initiating cytoreduction and response to conventional therapies in 1446 patients with essential thrombocythemia (ET), 267 (17%) of which wereCALR-mutated. In low risk patients, time from diagnosis to cytoreduction was shorter inCALR-positive than in the other genotypes (2 center dot 8, 3 center dot 2, 7 center dot 4 and 12 center dot 5 years forCALR,MPL,JAK2V617F and TN, respectively,P < 0 center dot 0001). A total of 1104 (76%) patients received cytoreductive treatment with hydroxycarbamide (HC) (n = 977), anagrelide (n = 113), or others (n = 14). The estimated cumulative rates of complete haematological response (CR) at 12 months were 40 % and 67% inCALRandJAK2V617F genotypes, respectively. Median time to CR was 192 days forJAK2V617F, 343 for TN, 433 forMPL, and 705 forCALRgenotypes (P < 0 center dot 0001). Duration of CR was shorter inCALR-mutated ET than in the remaining patients (P = 0 center dot 003). InCALR-positive patients, HC and anagrelide had similar efficacy in terms of response rates and duration.CALR-mutated patients developed resistance/intolerance to HC more frequently (5%, 23%, 27% and 15% forJAK2V617F,CALR,MPLand TN, respectively;P < 0 center dot 0001). In conclusion, conventional cytoreductive agents are less effective inCALR-mutated ET, highlighting the need for new treatment modalities and redefinition of haematologic targets for patients with this genotype.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results